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Introduction
There is a strong association between blood cholesterol and the development of
ischaemic heart disease (IHD). The Scandinavian Simvastatin Survival Study
(4S) was the first of several large-scale clinical trials of an HMG-CoA reductase
inhibitor (statin) on cardiovascular events and mortality in patients with known
coronary heart disease.1 Treatment with simvastatin resulted in a 37% reduction
in non-fatal myocardial infarction (MI), a 37% decrease in revascularisation
procedures, and a 42% reduction in deaths attributable to IHDs. Overall
mortality was reduced by 30%. Subsequent large clinical trials such as the
Cholesterol And Recurrent Events (CARE) Trial2 and Long-term Intervention
with Pravastatin In Ischaemic Disease (LIPID) study,3 showed that lower-risk
patients also benefited from statins.
Diet modification alone is insufficient to reduce cholesterol level in the
majority of patients. For these patients, statins are needed as they are efficacious
and reasonably safe. We set out to study coronary heart disease patients
requiring lipid-lowering therapy and to analyse the costs, benefits and
cost-effectiveness of treating hypercholesterolaemia with statins in these
patients.
Methods
Effect of diet and statin therapy
Patients were recruited from the Cardiac Clinic at Sai Ying Pun between
November 1996 and January 1997. Patients were included if they had not had
their cholesterol checked in the previous 2 years and were diagnosed as having
IHD, by virtue of a clinical diagnosis of IHD or angina, a history of MI, positive
exercise ECG or thallium scan, coronary angiography showing any significant
stenosis, or prescription of nitrates as anti-anginal therapy. Subjects were seen
and plasma lipid profile was measured at the time of recruitment, after dietary
class, and 3 and 6 months after statin prescription.
Cost-effectiveness of dietary intervention in lowering serum cholesterol
The cost-effectiveness of dietary intervention was assessed in those patients
who were started on cholesterol-lowering therapy for the first time. Drug therapy
would be started if the plasma total cholesterol (TC) exceeded 5.2 mmol/L and
dietary modification for at least 3 months had failed.4 We used this period to
assess the effectiveness of diet. All hypercholesterolaemic patients were asked to
attend an afternoon dietary class (3 hours) run by dieticians. The cost in terms of
dietician time and the cholesterol-lowering effect of the dietary intervention were
used to calculate a cost-effectiveness ratio.
Cost-effectiveness of statins in lowering plasma cholesterol
Assessment of costs
Patients were assumed to receive 40 mg daily of pravastatin, as in the
CARE study.2 The acquisition cost of a 20 mg tablet of pravastatin was HK$7.67
for hospitals in the Hong Kong Hospital Authority. A telephone survey of
10 local private clinics indicated that the market price of a full lipid profile
was $440.
Key Messages
1. These results suggest that a
period of non-pharmacological
intervention including dietary
classes lowers the blood choles-
terol of patients with coronary
heart disease. The use of statins
can improve the lipid profiles of
these patients further.
2. For Hong Kong patients with
myocardial infarction and
average cholesterol levels on
statin therapy, the gross cost
per event prevented or per
quality-adjusted life year gained
is substantial; the potential
benefits  and savings may
outweigh the costs.
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Assessment of benefits
We assessed the benefits of treating a hypothetical cohort
of Hong Kong patients with the same demographics
and prognosis as in the CARE study. As there were no
local data on the long-term benefit of statins, we used
the outcome data of the CARE study. Patients in
CARE were American and Canadian men (n=3583)
and post-menopausal women (n=576), aged 21 to 75 years,
who had an acute MI 3 to 20 months previously. The
entry criteria included plasma TC levels <240 mg/dL
(6.2 mmol/L), low-density lipoprotein (LDL) cholesterol
levels of 115 to 174 mg/dL (3.0 to 4.5 mmol/L), fasting
triglyceride levels of <350 mg/dL (4.0 mmol/L), fasting
glucose levels of no more than 220 mg/dL (12.2 mmol/L),
left ventricular ejection fractions of no less than 25%, and
no symptomatic congestive heart failure. The patients were
randomised to double-blind treatment with either placebo
(n=2078) or pravastatin (n=2081) for a median period of 5
years.
Benefits evaluated included (i) benefits to the hospital:
the prevention of IHD (costs of hospitalisation, clinic
attendance, cardiac investigations, cardiac intervention
procedures, rehabilitation), and other cardiovascular diseases
(eg stroke, peripheral vascular disease), and (ii) patient
benefits: reduction in loss of earnings. We used data from
the CARE study to estimate the number of cardiac events
prevented by treatment with statins.
Cost-effectiveness analysis
The cost-effectiveness in terms of reduction in cardiac
events and mortality was analysed from the perspective of
a hospital-based cardiological service providing in-patient
and out-patient care, specifically the diagnosis, treatment,
rehabilitation, follow-up and secondary prevention of
IHD.
Cost-utility analysis
In our cost-utility analysis, the endpoint was gross cost
per quality-adjusted life year (QALY) gained. In the 4S
study, the quality of life (QOL) in their population of
post-MI patients was 0.88. Other studies reported the
QOL as between 0.8 and 0.9. We therefore used 0.85.
Based on official statistics, the remaining average life
expectancy was estimated to be 16.7 and 22.3 years
respectively in males and females. We assumed that at age
59 a prior MI decreased life expectancy by half, as observed
in the 4S study.
Cost-benefit analysis
Benefits and savings arose from life years gained,
prevention of MIs, strokes and procedures. The life years
gained was translated to earnings according to the
employment pattern for the working population aged 55 to
59 years. Prevention of non-fatal MIs would lead to fewer
hospitals admissions. The average cost of an admission to
Queen Mary Hospital for an acute MI patient was $46 720.
The median cost of a percutaneous transluminal coronary
angioplasty (PTCA) procedure was $35 000 and the me-
dian price for a stent was $12 000. Calculation of benefits
due to stroke prevention was based on the assumption of
equal numbers of severe and mild disabilities prevented.
Severe disabilities was assumed to require attendance at a
day hospital with supervised daily training ($1430 per
attendance). Mild disabilities were assumed to require com-
munity nursing services (twice per week at $360 per visit).
Results
Effect of diet and statin therapy
There were 106 males and 95 females (mean age, 71±10
years) recruited. Results of lipid profiles are shown in
Tables 1 to 3. For those patients who had raised cholesterol
levels in their first blood test, they were asked to attend
diet class and have their second blood test measured 3
months later.
Cost-effectiveness of dietary intervention and statin
therapy in lowering serum cholesterol
The cost of the dietary intervention was $55.44 per patient.
The mean reductions in TC and LDL cholesterol after the
dietary intervention were 0.24 mmol/L and 0.22 mmol/L,
respectively. Therefore, the cost per mmol/L reduction was
estimated as $231 for TC and $252 for LDL cholesterol.
The mean cost of statin therapy was $8.41 per patient
per day. The average LDL cholesterol level of patients
who had received statin treatment until the end of the study
decreased from 4.58±0.77 to 3.59±0.86 (P=0.003). The
mean reduction due to statin treatment was 0.99 mmol/L
per patient. The cost-effectiveness of statin therapy was
$8.49 per patient per day per mmol/L reduction in LDL
cholesterol.
Cost-effectiveness of statins in lowering plasma
cholesterol
Costs and benefits of lipid-lowering therapy with a statin
The cost of the lipid measurements and prescription of
Table 1.  Lipid profile
Profile* Blood test 1 (n=143) Blood test 2 (n=40) Blood test 3 (n=30) Blood test 4 (n=16)
Mean ± SD (mmol/L) Mean ± SD (mmol/L) Mean ± SD (mmol/L) Mean ± SD (mmol/L)
TC 5.30 ± 0.99 5.80 ± 0.87 5.53 ± 0.95 5.52 ± 0.94
TG 1.39 ± 0.92 1.60 ± 1.10 1.57 ± 1.21 1.48 ± 0.65
HDL 1.17 ± 0.38 1.25 ± 0.42 1.20 ± 0.34 1.20 ± 0.32
LDL 3.51 ± 0.89 3.93 ± 0.82 3.60 ± 1.05 3.63 ± 0.84
* TC denotes total cholesterol, TG triglycerides, HDL high-density lipoprotein cholesterol, and LDL low-density lipoprotein cholesterol
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40 mg pravastatin daily for 2081 patients was estimated to
be $12 818 960 and $58 258 635.5, respectively. Total
undiscounted cost was $71 077 596. The cost-effectiveness
ratios are set out in Table 4. Total undiscounted benefits and
savings would be $90 144 231 (Table 5). As the potential
benefits and savings exceed the costs, there is a net benefit
of $19 066 635 before discounting. After discounting at 6%,
benefits and savings ($75 944 058) are still larger than
the discounted costs ($60 512 876), resulting in a net
benefit of $15 431 182. Pravastatin treatment for 5 years
resulted in 343.12 QALYs gained. Net cost per QALY
gained was $71 032 ([$71 077 596 - $46 704 975]/343.12)
and after discounting at 6%, $73 218 ([$60 512 876 -
$39 347 668]/289.07) [Table 6].
Cost-effectiveness of statins under different
circumstances
The cost-effectiveness of statins was also estimated for
other types of patient population. In a patient population
similar to 4S, drugs and biochemical monitoring would cost
$8331.23 per patient per year. It would cost $524 867.49 to
prevent one coronary event and $1 357 990.49 to prevent
one death. In a patient population similar to WOSCOP
study,5 drugs and biochemical monitoring would cost
$7359.10 per patient per year. It would cost $1 596 924.70
to prevent one coronary event and $4 054 864.10 to prevent
one death. In a patient population similar to AFCAPS/
TexCAPS study,6 drugs and biochemical monitoring
would cost $5707.48 per patient per year. It would cost
$1 461 114.88 to prevent one coronary event. In this study,
there was no significant reduction in mortality.
Discussion
Dietary class
These results suggest that dietary classes help to lower
the cholesterol level of patients with coronary heart disease.
Table 2.  Effect of diet class on lipid profiles (n=40)
Profile* Before class After class Change in mean
Mean ± SD Mean ± SD (mmol/L)
(mmol/L) (mmol/L)
TC 6.04 ± 0.72 5.80 ± 0.87 -0.24†
TG 1.63 ± 1.16 1.60 ± 1.10 -0.03†
HDL 1.21 ± 0.42 1.24 ± 0.42 -0.03†
LDL 4.15 ± 0.56 3.93 ± 0.82 -0.22†
* TC denotes total cholesterol, TG triglycerides, HDL high-density lipoprotein
cholesterol, and LDL low-density lipoprotein cholesterol
† P<0.05
Table 3.  Effect of statin on lipid profiles (n=16)
Profile* Before statin Blood test 3 Blood test 4 Change
Mean ± SD Mean ± SD Mean ± SD in mean
(mmol/L) (mmol/L) (mmol/L) (mmol/L)
TC 6.33 ± 0.73 5.62 ± 1.20 5.52 ± 0.94 -0.81†
TG 1.57 ± 0.84 1.59 ± 1.31 1.48 ± 0.65 -0.09†
HDL 1.14 ± 0.34 1.25 ± 0.31 1.23 ± 0.30 -0.09†
LDL 4.58 ± 0.77 3.64 ± 1.25 3.59 ± 0.86 -0.99†
* TC denotes total cholesterol, TG triglycerides, HDL high-density lipoprotein
cholesterol, and LDL low-density lipoprotein cholesterol
† P<0.05
Table 4.  Cost-effectiveness of statin treatment
Event* No. prevented HK$ cost/event prevented
Mean (95% CI)
No discounting 6% discounting
Deaths 16 4 442 350 3 782 055
(1 537 736 to undefined†) (1 309 173 to undefined†)
CHD deaths 23 3 090 330 2 630 995
(1 584 785 to undefined†) (1 349 228 to undefined†)
Non-fatal MI 38 1 870 463 1 592 444
(1 103 094 to 10 755 162) (939 134 to 9 156 554)
Fatal or confirmed non-fatal MI 50 1 421 552 1 210 258
(911 251 to 4 442 350) (775 806 to 3 782 055)
CHD deaths or non-fatal MI 62 1 146 413 976 014
(764 275 to 3 057 101) (650 676 to 2 602 704)
Procedures 97 732 759 623 844
(534 716 to 1 318 966) (455 238 to 1 122 919)
Fatal and non-fatal strokes 24 2 961 566 2 521 370
(1 822 502 to 23 692 532) (1 551 612 to 20 170 959)
All events (deaths + non-fatal MIs + non-fatal 179 397 082 338 061
strokes + procedures)
* CHD denotes coronary heart disease, and MI myocardial infarction
† The upper limit is undefined as the 95% confidence interval crosses zero
Table 5.  Cost-benefit analysis
Source of benefits and savings* Amount (HK$)
Benefits
Potential increase in earnings due to life 36 596 390
years gained
Savings
Acute admission from non-fatal MI 21 495 692
prevention
PTCA procedures prevented 21 385 868
Deployment of stents prevented 22 475 155
Community nursing services for mild 22 408 876
disabilities prevented from stroke
Geriatric day hospital for severe disabilities 33 582 077
prevented from stroke
Total discounted benefits and savings 75 944 058
* MI denotes myocardial infarction, and PTCA percutaneous transluminal
coronary angioplasty
Table 6.  Gross and net cost per QALY gained
Amount (HK$)
No discounting 6% discounting
Gross cost/QALY gained 207 151 209 336
Net cost/QALY gained 271 032 273 218
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The use of statins can improve the lipid profiles of these
patients but at a considerable cost. Dietary intervention is
less effective than drug treatment in lowering cholesterol
but it is inexpensive. Since a proportion of patients
respond to dietary modification, long-term prescription of
expensive lipid-lowering drugs might be avoided in these
patients.
Cost-effectiveness of lipid-lowering therapy
Previous clinical trials suggest that all at-risk patients will
benefit from treatment with statins, regardless of the level
of their risk. The cost-effectiveness of statins depends on
the risk of coronary heart disease. For patients at high risk
treatment with a statin has been shown to be cost-effective.
In our analysis of a patient population similar to that in the
CARE study, the gross cost per QALY gained is substantial.
Care should be taken in the prescription of statins and
in deciding whom to treat. Cholesterol per se is a weak
indicator of future coronary risk. The majority of coronary
event patients have average cholesterol levels. To be more
cost-effective, statins should be prescribed according to the
baseline risk of individual patients.
Treatment with statins can also reduce the risk of stroke,
the second leading cause of death. We therefore included
stroke in our analysis and found that its inclusion increases
the cost-effectiveness of statin therapy. Prevention of
heart attacks and strokes result in other benefits and
savings that ultimately outweigh the costs of statins.
These include increased life expectancy and earnings, as
well as avoidance of costs due to acute hospitalisation,
more frequent out-patient follow-up, procedures, and
rehabilitation.
Conclusions
If coronary heart disease patients in Hong Kong derive as
much benefit from statin therapy as patients in clinical trials,
statin therapy may be economically sound. Although the
short-term costs appear high, there are long-term benefits
in terms of lower mortality, fewer hospitalisations and
cardiac catheterizations, angioplasties and coronary artery
bypass operations, especially if stroke reduction is also
considered. Therefore, our analysis supports the use of
statins in addition to dietary intervention for patients with
coronary heart disease. Cholesterol-lowering therapy in
patients with coronary heart disease should be enthusiasti-
cally implemented and allocated appropriate resources.
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